News

Scientists and clinicians from five leading UK universities will begin a groundbreaking clinical trial next year to test a possible cure for HIV infection.

Leading organisations have joined forces to rapidly assess and communicate the benefits and risks of vaccines.

Researchers have developed a more detailed picture of the protein largely responsible for enabling HIV to enter human immune cells and cause infection.

The award recognises the companies' agreement to explore Horizon’s first-in-class kinase target program HD-001 as a means of developing novel therapies for multiple cancer types.

'Resistance breaker’ compounds have been described as the most important innovation in the discovery of new antibiotics since Alexander Fleming’s original breakthrough.

Company to accelerate clinical development of antibodies IMAB362 and IMAB027 for the treatment of cancer.

The investments are a direct response to the growing diabetes epidemic.

The partnership is based on Oncodesign's Nanocyclix® technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.

Industry leader brings broad strategic and licensing experience in development and commercial stage biopharmaceutical companies.

Summit will address the interpretation of the anticipated Final Rule and the larger implications of Medicaid expansion.